ASLN:NSD-ASLAN Pharmaceuticals Limited (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.67

Change

+0.15 (+9.87)%

Market Cap

USD 0.11B

Volume

1.26M

Avg Analyst Target

USD 8.00 (+379.04%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore. Address: 83 Clemenceau Avenue, Singapore, Singapore, 239920

Company Website : http://aslanpharma.com

Address : 83 Clemenceau Avenue, Singapore, Singapore, 239920

Employees : 18

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.49

52 Week High : 6.75

Short Ratio : 0.63

52 Week Low : 1.38

Shorted Shares : 474,745

200 Day Moving Average : 2.78

Shorted Shares Previous Month : 1,184,422

50 Day Moving Average : 2.20

Short Percentage : 2.00%

Shares Held by Institutions : 40.09%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.86 (-1.41%)

 USD139.56B 40.85 31.63
BNTX BioNTech SE

-13.62 (-4.66%)

 USD70.91B 16.26 11.68
REGN Regeneron Pharmaceuticals Inc

-2.55 (-0.43%)

 USD62.24B 10.69 7.94
VRTX Vertex Pharmaceuticals Incorpo..

-3.13 (-1.70%)

 USD47.75B 24.27 16.15
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-16.37 (-4.27%)

 USD35.80B N/A N/A
SGEN Seagen Inc

-3.09 (-1.74%)

 USD32.33B 55.44 43.27
GMAB Genmab A/S

-0.46 (-1.01%)

 USD30.35B 77.92 9.04
ALNY Alnylam Pharmaceuticals Inc

-6.55 (-3.31%)

 USD23.50B N/A N/A
RPRX Royalty Pharma plc

-0.93 (-2.46%)

 USD22.91B 30.56 12.22

ETFs Containing ASLN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.74% 62% D- 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.74% 62% D- 30% F
Trailing 12 Months  
Capital Gain -1.18% 51% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.18% 51% F 23% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.95% 31% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.95% 31% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 67.34% 46% F 26% F
Risk Adjusted Return -1.41% 31% F 19% F
Market Capitalization 0.11B 22% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.10 81% B- 94% A
Price/Book Ratio 1.36 87% B+ 74% C
Price / Cash Flow Ratio -7.03 50% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -65.53% 44% F 24% F
Return on Invested Capital -126.54% 12% F 5% F
Return on Assets -27.19% 46% F 13% F
Debt to Equity Ratio -149.56% 96% A 95% A
Technical Ratios  
Short Ratio 0.63 89% B+ 84% B
Short Percent 1.81% 80% B- 63% D
Beta 2.49 6% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.